Abstract
Corneal allografts are the oldest, most common, and most successful transplants performed on humans and animals. The cornea is endowed with a constellation of unique factors that contribute to its immune privilege and the low incidence of immune rejection. In spite of this immune privilege, 10 percent of first-time corneal grafts will undergo immune rejection. Several novel therapeutic strategies hold promise for modulating the alloimmune response by either promoting antigen-specific tolerance or redirecting the host's response from a Th1 pathway toward a Th2 pathway.
Original language | English (US) |
---|---|
Pages (from-to) | 173-196 |
Number of pages | 24 |
Journal | International Reviews of Immunology |
Volume | 21 |
Issue number | 2-3 |
DOIs | |
State | Published - 2002 |
Keywords
- Cornea
- Immune modulation
- Immune privilege
- Keratoplasty
- Rejection
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology